SG11201503051QA - Formulations of pyrimidinedione derivative compounds - Google Patents
Formulations of pyrimidinedione derivative compoundsInfo
- Publication number
- SG11201503051QA SG11201503051QA SG11201503051QA SG11201503051QA SG11201503051QA SG 11201503051Q A SG11201503051Q A SG 11201503051QA SG 11201503051Q A SG11201503051Q A SG 11201503051QA SG 11201503051Q A SG11201503051Q A SG 11201503051QA SG 11201503051Q A SG11201503051Q A SG 11201503051QA
- Authority
- SG
- Singapore
- Prior art keywords
- formulations
- derivative compounds
- pyrimidinedione derivative
- pyrimidinedione
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261715766P | 2012-10-18 | 2012-10-18 | |
PCT/US2013/065760 WO2014063101A1 (fr) | 2012-10-18 | 2013-10-18 | Formulations de composés dérivés de pyrimidinedione |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201503051QA true SG11201503051QA (en) | 2015-05-28 |
Family
ID=49554481
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201503051QA SG11201503051QA (en) | 2012-10-18 | 2013-10-18 | Formulations of pyrimidinedione derivative compounds |
Country Status (11)
Country | Link |
---|---|
US (2) | US9629841B2 (fr) |
EP (1) | EP2908808A1 (fr) |
JP (2) | JP6266635B2 (fr) |
CN (2) | CN104853752B (fr) |
AU (1) | AU2013330993B2 (fr) |
BR (1) | BR112015008927A2 (fr) |
CA (1) | CA2888883A1 (fr) |
EA (2) | EA028481B1 (fr) |
MX (1) | MX2015004973A (fr) |
SG (1) | SG11201503051QA (fr) |
WO (1) | WO2014063101A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
WO2015103490A1 (fr) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Formes galéniques antivirales solides |
CA2937365C (fr) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Formulation en granules de 5-methyl-1-phenyl-2-(1h)-pyridone et methode de fabrication associee |
MX2022011058A (es) * | 2020-03-05 | 2022-12-13 | Aurigene Discovery Tech Ltd | Composiciones farmaceuticas de un inhibidor de cinasa. |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4442257A1 (de) * | 1994-11-28 | 1996-05-30 | Beate Dr Podschun | Sparsomycin |
US6177101B1 (en) | 1998-06-11 | 2001-01-23 | Pharmacia & Upjohn Company | Delavirdine high strength tablet formulation |
AU784340B2 (en) | 1999-12-23 | 2006-03-16 | Pfizer Products Inc. | Pharmaceutical compositions providing enhanced drug concentrations |
GB0009522D0 (en) * | 2000-04-19 | 2000-06-07 | Smithkline Beecham Plc | Composition |
US6489363B2 (en) * | 2000-10-11 | 2002-12-03 | Cephalon, Inc. | Pharmaceutical solutions of modafinil compounds |
WO2006066063A1 (fr) * | 2004-12-15 | 2006-06-22 | Elan Pharma International Ltd. | Formulations renfermant des nanoparticules de tacrolimus |
US20070082952A1 (en) * | 2005-10-06 | 2007-04-12 | Benjamin Eric J | Pharmaceutical compositions, methods of preparation thereof, and methods of treatment |
CN101842360B (zh) * | 2007-09-17 | 2014-12-17 | 艾伯维巴哈马有限公司 | 抗感染嘧啶及其用途 |
TWI437994B (zh) * | 2007-09-17 | 2014-05-21 | Abbvie Bahamas Ltd | 抗感染劑及其用途 |
US20100166861A1 (en) * | 2008-12-29 | 2010-07-01 | Kelly Noel Lynch | Pharmaceutical formulations of sevalamer, or salts thereof, and copovidone |
CA2790707A1 (fr) * | 2010-03-01 | 2011-09-09 | Concert Pharmaceuticals Inc. | Derives de fluorouracile |
CN104023726A (zh) * | 2011-10-21 | 2014-09-03 | 艾伯维公司 | 用于治疗hcv的一种或多种daa的联合治疗(例如,与abt-072或abt-333) |
-
2013
- 2013-10-18 CN CN201380066499.XA patent/CN104853752B/zh not_active Expired - Fee Related
- 2013-10-18 US US14/058,071 patent/US9629841B2/en active Active
- 2013-10-18 CN CN201811208736.2A patent/CN109260207A/zh active Pending
- 2013-10-18 BR BR112015008927A patent/BR112015008927A2/pt not_active IP Right Cessation
- 2013-10-18 AU AU2013330993A patent/AU2013330993B2/en not_active Ceased
- 2013-10-18 CA CA2888883A patent/CA2888883A1/fr not_active Abandoned
- 2013-10-18 MX MX2015004973A patent/MX2015004973A/es unknown
- 2013-10-18 EA EA201590752A patent/EA028481B1/ru not_active IP Right Cessation
- 2013-10-18 EP EP13789411.9A patent/EP2908808A1/fr not_active Withdrawn
- 2013-10-18 SG SG11201503051QA patent/SG11201503051QA/en unknown
- 2013-10-18 JP JP2015538082A patent/JP6266635B2/ja not_active Expired - Fee Related
- 2013-10-18 EA EA201791354A patent/EA032913B1/ru not_active IP Right Cessation
- 2013-10-18 WO PCT/US2013/065760 patent/WO2014063101A1/fr active Application Filing
-
2017
- 2017-03-10 US US15/455,477 patent/US10201542B2/en active Active
- 2017-12-19 JP JP2017242601A patent/JP2018065858A/ja not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
US20170181973A1 (en) | 2017-06-29 |
US10201542B2 (en) | 2019-02-12 |
AU2013330993A1 (en) | 2015-05-07 |
JP6266635B2 (ja) | 2018-01-24 |
CN104853752B (zh) | 2018-10-23 |
BR112015008927A2 (pt) | 2017-07-04 |
US9629841B2 (en) | 2017-04-25 |
EP2908808A1 (fr) | 2015-08-26 |
EA032913B1 (ru) | 2019-08-30 |
MX2015004973A (es) | 2015-07-17 |
CN109260207A (zh) | 2019-01-25 |
EA201791354A3 (ru) | 2018-03-30 |
CN104853752A (zh) | 2015-08-19 |
CA2888883A1 (fr) | 2014-04-24 |
EA028481B1 (ru) | 2017-11-30 |
JP2018065858A (ja) | 2018-04-26 |
EA201791354A2 (ru) | 2017-11-30 |
US20140113921A1 (en) | 2014-04-24 |
WO2014063101A1 (fr) | 2014-04-24 |
AU2013330993B2 (en) | 2018-03-01 |
JP2015534985A (ja) | 2015-12-07 |
EA201590752A1 (ru) | 2016-02-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL277652A (en) | Stable aqueous formulations of adlimumab | |
HK1212701A1 (zh) | 恩雜魯胺製劑 | |
HK1213174A1 (zh) | 穩定的含水依那西普製劑 | |
EP2814487A4 (fr) | Formulations de bendamustine | |
HK1210914A1 (en) | Formulations of clomazone | |
FI2827862T3 (fi) | Bendamustiinin formulaatioita | |
HK1207081A1 (en) | Crystalline forms of dihydropyrimidine derivatives | |
SG11201503051QA (en) | Formulations of pyrimidinedione derivative compounds | |
ZA201502350B (en) | Solid form of hihydro-pyrido-oxazine derivative | |
HUE036665T2 (hu) | Dihidro-pirido-oxazin származék szilárd formái |